ACUTE MYELOID LEUKEMIA, IN RELAPSE
Clinical trials for ACUTE MYELOID LEUKEMIA, IN RELAPSE explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA, IN RELAPSE trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA, IN RELAPSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Groundbreaking T-Cell therapy trial offers hope for kids with tough leukemia
Disease control Recruiting nowThis early-phase study is testing a new, genetically modified T-cell therapy called SC-DARIC33 in children and young adults (up to age 30) whose acute myeloid leukemia has returned or not responded to standard treatments. The main goals are to see if the therapy is safe to make a…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Ready-Made immune cells tested to fight tough blood cancers
Disease control Recruiting nowThis early-stage study is testing a new type of treatment called MT-401-OTS, which uses specially prepared immune cells from healthy donors to fight cancer. It is for adults aged 65+ with certain types of relapsed acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) wh…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Marker Therapeutics, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
New hope for leukemia patients out of options
Disease control Recruiting nowThis study is testing a new drug called AB8939 for people with acute myeloid leukemia (AML) that has come back or hasn't responded to previous treatments. The main goals are to find a safe dose and see if the drug helps control the cancer. It's for patients who have already tried…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: AB Science • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
First human trial launches for experimental blood cancer drug
Disease control Recruiting nowThis early-stage study is testing a new drug called APL-4098 in adults with advanced forms of blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Researchers want to find the safest dose and see how well the drug works when given alone or combined …
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Scientists test supercharged immune cells in fight against tough leukemia
Disease control Recruiting nowThis early-stage study is testing a new treatment for adults with acute myeloid leukemia (AML) that has returned or not responded to other therapies. Researchers are combining specially trained immune cells, called NK cells, from a family donor with a drug called atezolizumab. Th…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New CAR-T therapy targets Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial is testing a new CAR-T cell therapy called ARD103 for patients with acute myeloid leukemia or myelodysplastic syndrome that has returned or hasn't responded to previous treatments. The study aims to find the safest and most effective dose while checking if …
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: ARCE Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for Tough-to-Treat leukemia: experimental drug enters human trials
Disease control Recruiting nowThis study is testing whether adding an experimental drug called ziftomenib to standard leukemia treatments is safe and effective. It will involve 420 adults with acute myeloid leukemia (AML) who have specific genetic changes in their cancer cells. The main goals are to find the …
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New immune cell therapy tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis is a first-in-human study to test the safety and find the right dose of a new type of CAR T-cell therapy for patients with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The therapy involves modifying a patient's own immune cells to tar…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
First human test of new leukemia drug duo offers hope for tough cases
Disease control Recruiting nowThis is an early safety study for adults whose acute myeloid leukemia (AML) has come back or not responded to standard treatment. Researchers are testing a new combination of two drugs, bomedemstat and venetoclax, to find the safest dose and see if the body can tolerate them. The…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Terrence J Bradley, MD • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Hope for young leukemia patients: new 3-Drug combo trial launches
Disease control Recruiting nowThis study is testing whether adding a drug called venetoclax to two other medications (5-azacitidine and vorinostat) followed by standard chemotherapy can better control a severe blood cancer called acute myeloid leukemia (AML) in children and young adults. It is for patients wh…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
First human test of novel Cancer-Fighting particle for aggressive leukemia
Disease control Recruiting nowThis early-stage study is testing the safety of a new drug called C6 ceramide nanoliposome (CNL) in adults whose acute myeloid leukemia (AML) has returned or not responded to prior treatments. The main goal is to find a safe dose for future studies, as CNL has shown promise in la…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Keystone Nano, Inc • Aim: Disease control
Last updated Mar 04, 2026 15:30 UTC
-
Massive 4000-Patient study launches to map the fight against tough blood cancer
Knowledge-focused Recruiting nowThis study aims to collect real-world data on how patients with acute myeloid leukemia (AML) that has returned or is resistant to treatment fare across Europe. It will follow 4000 patients to understand survival rates, treatment responses, and which therapies are used in practice…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC